Introduction: Neuronatin is a protein that is specifically expressed in the nervous system in the course of embryonal brain development, and its expression is limited to the pituitary gland in normal human adults. Neuronatin expression has been reported in some types of tumor. The purpose of this study was to clarify the significance of neuronatin expression in pulmonary non-small cell carcinoma.
N euronatin is a protein that is specifically expressed in the nervous system in the course of embryonal brain development in mammals. Neuronatin was initially discovered in rats during a search for genes considered to be important for development of the central nervous system. 1 In the mammalian fetus, neuronatin seems to contribute to the development and maturation of the hindbrain and pituitary gland. During later embryogenesis, the neuronatin gene is strongly expressed in the major part of the central and peripheral nervous system. 2 In human brain, neuronatin mRNA is selectively expressed during fetal development, but becomes repressed in adulthood. The deduced neuronatin protein has two distinct domains, a hydrophobic N-terminal domain and a basic C-terminal domain, and exhibits homology with members of the proteolipid class of proteins that function as regulatory subunits of membrane channels. 3 As a result of variable splicing, neuronatin mRNA exists in two forms, alpha and beta. 4 In addition, neuronatin is known as a paternally expressed imprinted gene. 5 In normal human adults, distinct expression of neuronatin is found only in the anterior pituitary gland. 6 Nevertheless, mRNA expression of neuronatin has been reported in pituitary adenoma, 6, 7 myxoid liposarcoma, 8 Wilms' tumor 9 and medulloblastoma 10 in humans, as well as in prostatic cancer with neuroendocrine features 11 and thyroid stimulating hormone-producing tumors 12 in mice. Furthermore, high expression has recently been reported in a tamoxifen-resistant mammary carcinoma cell line. 13 Okubo et al. have reported that neuronatin is more frequently and highly expressed in large cell neuroendocrine carcinoma than in small cell carcinoma of the lung. 14 The purpose of this study was to clarify the significance of neuronatin expression in pulmonary non-small cell carcinoma by immunohistochemical staining, and to investigate the usefulness of neuronatin gene expression as a prognostic marker for these tumors.
MATERIALS AND METHODS

Tissue Specimens and Histologic Typing
Materials used in the present study consisted of surgically resected primary pulmonary carcinoma specimens from 92 patients, and included 51 adenocarcinomas and 41 squamous cell carcinomas. Lobectomy and mediastinal and pul-monary hilar lymph node dissection were performed for all the cases examined at the University Hospital of Tsukuba (Ibaraki, Japan). Patients with adenocarcinoma underwent surgery during the period from September 1997 to August 1999, and those with squamous cell carcinoma from September 1996 to August 1999. In principle, all patients in these periods were included, but patients with pathologic stage IV lung carcinoma were excluded (two patients with adenocarcinoma). Patients with previous treatment history were also excluded. The surgically resected specimens were fixed routinely in 10% formalin and embedded in paraffin for histological examination. In some cases, fresh frozen specimens were also preserved for Western blot analysis. Informed consent was obtained from all patients for specimen collection. All the cases were classified by pathologic stage according to the International System for Staging Lung Cancer. 15 Histologic typing was performed according to the 2004 edition of the World Health Organization classification of lung tumors. 16 
Immunohistochemical Staining
For immunohistochemical staining for neuronatin, 2-m sections were cut from 10% formalin-fixed and paraffin-embedded specimens. Sections were selected to show representative histology and adequate cut surface of the tumor. The sections were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol. For antigen retrieval, the sections were placed in citrate buffer (pH 6.0) and heat-treated in an autoclave at 121°C for 15 minutes. They were stained with an automatic staining machine (Autostainer plus; Dako Cytomation Co., Ltd., Kyoto, Japan) using an antineuronatin antibody (polyclonal antibody S-14; Santa Cruz Biotechnology, Santa Cruz, CA) at a dilution of 1:50. A Histofine Simple Stain MAX-PO(G) Kit (Nichirei, Tokyo, Japan) provided the second antibody and the detection system. The sections were counterstained with hematoxylin. The slides were evaluated by standard light microscopy. For positive or negative controls, we used specimens that had been shown to be positive or negative in a previous study by in situ hybridization (data not shown). 14 No tumors diffusely showed positive reaction against antineuronatin antibody. The positive area in the maximum cut surface of the tumor was very limited. A tumor was judged to be positive for neuronatin expression when Ͼ5% of the cells in the area concerned were stained immunohistochemically. The specificity of the primary antibody was confirmed by staining in the absence of primary antibody.
Preparation of Cell Extracts and Western Blot Analysis
Frozen specimens were sliced into 7-m-thick sections, and six sections were placed in lysis buffer (50 mM Tris HCl, pH 6.8, 4% SDS, 6% 2-mercaptoethanol, 10% glycerol). A micropipette and injector with a 27G needle were used to macerate the tissue and dissolve proteins, followed by incubation for 30 minutes, maintaining the temperature at 4°C through all procedures. Next, the homogenate was centrifuged at 21000g for 30 minutes at 4°C. The supernatant fluid was used as the total cell lysate. The cell lysate was boiled at 97°C for 3 minutes and loaded onto gels at 20 l per well. Electrophoresis was performed at 10 mA per gel. Proteins were transferred from gels to PVDF membranes with a Trans Blot Semi-Dry Transfer Cell (BioRad Laboratories, Tokyo, Japan) at 15 V for 50 minutes. To block nonspecific binding, the membrane was incubated in 1.5% blocking reagent (Roche Diagnostics, Basel, Switzerland) for 30 minutes at room temperature. The subsequent immunostaining was performed with a kit (Enhanced Alkaline Phosphatase Western Blotting Kit, Goat; Oxford Biomedical Research, Inc., Oxford, MI) according to the manufacturer's instructions. The primary antibody (1:100 dilution) was the same product as used for immunohistochemical staining (polyclonal antibody S-14; Santa Cruz Biotechnology). 
Statistical Analysis
RESULTS
Patient Background
Of the 51 adenocarcinoma patients, the mean age was 70.0 years (range 37-80 years), and there were 27 male and 24 female patients. The total numbers of patients with pathologic stage I/II/III disease were 32/7/12, respectively. With respect to smoking index (SI), 23 patients (45.1%) were heavy smokers (SI Ն 600).
Of the 41 squamous cell carcinoma patients, the mean age was 67.2 years (range 44 -78 years), and there were 34 male and 7 female patients. The total numbers of patients with pathologic stage I/II/III disease were 17/8/16, respectively. With respect to SI, 37 patients (90.2%) were heavy smokers (SI Ն 600).
Comparison of the groups with adenocarcinoma and squamous cell carcinoma showed that the proportion of males and the proportion of heavy smokers were significantly higher in squamous cell carcinoma patients than in adenocarcinoma patients (p ϭ 0.0025 and p Ͻ 0.001, respectively). Patients with squamous cell carcinoma tended to have more advanced disease than did patients with adenocarcinoma, but the difference was not statistically significant (p ϭ 0.1229).
Immunohistochemical Staining for Neuronatin
First, we confirmed the specificity of the antibody used in this study. We detected a single immunoreactive band corresponding to neuronatin-␣ with an estimated molecular mass of 9 kD in an adenocarcinoma case that showed positive reaction by immunohistochemical staining (Figure 1) . Figure 2 shows light microscopic findings of neuronatin-positive cases. Positive cells were focally or diffusely distributed in the tumor. Neuronatin was detected in the cytoplasm, showing granular or reticular patterns, in both adenocarcinoma and squamous cell carcinoma. In most cases, nontumorous lung tissue did not show positive staining. Nevertheless, in some cases positive staining was observed to various degrees in macrophages, normal alveolar cells, or the nuclei of interstitial cells. Table 1 summarizes the associations between immunohistochemical results and the clinicopathological features of the patients examined. The frequency of neuronatin expression in tumor samples was significantly higher in males than in females, higher in SI Ն 600 than in SI Ͻ 600, and higher in squamous cell carcinoma than in adenocarcinoma. With respect to patient age and stage of disease, we found no significant differences between neuronatin-positive cases and negative cases.
Comparison of Patient Background and Immunohistochemical Staining
For adenocarcinoma, neuronatin positivity was observed more frequently in less-differentiated adenocarcinoma than in differentiated adenocarcinoma ( Table 2) .
For squamous cell carcinoma, we did not detect any significant differences between neuronatin-positive cases and neuronatin-negative cases with respect to gender, SI, stage of disease, and histological differentiation ( Table 3) .
Impact of Neuronatin Expression on Survival
In an attempt to evaluate the impact of neuronatin expression on survival, we analyzed overall survival for patients with adenocarcinoma and squamous cell carcinoma with respect to the results of immunohistochemical staining for neuronatin, gender, and histological differentiation. There were 11 deaths among the adenocarcinoma patients in the study, and 10 of them were lung carcinoma-related. On the other hand, there were 11 deaths among the squamous cell carcinoma patients, and seven of them were lung carcinoma- related. As a result, the total number of cases for which follow-up was possible for 5 years was 38 (74.5%) in adenocarcinoma and 29 (70.7%) in squamous cell carcinoma.
First, we found no significant difference in overall patient outcome between adenocarcinoma and squamous cell carcinoma (p ϭ 0.5552, 5-year survival rates 0.753 versus 0.670).
For adenocarcinoma, as Figure 3A shows, the outcome of patients with neuronatin-positive tumors was significantly worse than that of patients with neuronatin-negative tumors (p ϭ 0.0025, 5-year survival rates 0.407 versus 0.852). Especially as Figure 3B shows, about stage I adenocarcinoma cases (32 cases), overall survival rate of neuronatin positive cases is significantly lower than those of negative cases (p ϭ 0.0131). Nevertheless, in stage II and III cases, there is no significant difference of overall survival between positive and negative cases. Male patients had significantly worse treatment outcomes than did female patients (p ϭ 0.0194, 5-year survival rates 0.617 versus 0.908). Furthermore, patients with poorly differentiated adenocarcinoma had significantly worse outcomes than did patients with well-or moderately differentiated adenocarcinoma (p ϭ 0.0050 and 0.0266).
For squamous cell carcinoma, as Figure 3C shows, no significant difference was observed between the survival curves of patients with neuronatin-positive tumors and neuronatin-negative tumors (p ϭ 0.9880, 5-year survival rates 0.657 versus 0.688). In addition, there were no significant differences in outcome with respect to gender or histological differentiation.
DISCUSSION
The neuronatin gene is generally thought to be expressed only in the pituitary gland in normal adults. 6, 7 Nevertheless, it was recently reported that neuronatin is expressed in pancreatic ␤-cells 17 and hematopoietic progenitor cells. 18 Furthermore, RNA analysis has demonstrated neuronatin expression in some types of tumors. 8, 9, 10 As we reported previously, neuronatin is a unique gene that is highly expressed in large cell neuroendocrine carcinomas relative to small cell carcinomas of the lung. 14 There was only an imperfect correlation between neuronatin expression and the expressions of neuroendocrine markers such as CD56, chromogranin A, and synaptophysin among large-cell neuroendocrine carcinomas and small cell carcinomas. From these results, we postulated that neuronatin is not a specific marker of neuroendocrine differentiation but rather a marker for immature characteristics of large cell neuroendocrine carcinomas and small-cell carcinomas. We need more extensive comparative study between neuronatin expression and other NE markers in non-small cell carcinomas of the lung to conclude the biological meaning of neuronatin expression. In the present study, we examined neuronatin expression in squamous cell carcinomas and adenocarcinomas, the two common histological subtypes of lung carcinoma, and showed that neuronatin is expressed in both histological subtypes. Interestingly, neuronatin expression was significantly associated with poor prognosis of adenocarcinoma but not of squamous cell carcinoma. Although neuronatin is specifically expressed in the fetal nervous system in the course of brain development, it is not thought to be a neuroendocrine marker but, rather, an embryonal marker, except in the pituitary gland. Several reports of characteristic expression of neuronatin in some undifferentiated malignant tumors, such as liposarcoma and Wilms' tumors, support this speculation. 8, 9 This study provided little information about the functions of neuronatin. In adenocarcinoma, neuronatin-positive cases had significantly worse outcomes than did neuronatinnegative cases. The reason for this is unknown, but may be related to the fact that neuronatin tends to be expressed in undifferentiated carcinoma. In addition, other factors may affect this association, such as smoking or gender. There is a report that expression of neuronatin is related to resistance to toxins that disturb cationic gradients. 19 On the other hand, there is an early and marked increase in neuronatin expression when a thyroid-stimulating hormone-producing tumor is caused to regress by administration of thyroid hormone. 12 Furthermore, neuronatin expression is enhanced in a mammary tumor cell line that has acquired resistance to tamoxifen (an antiestrogen hormone agent). 13 These observations suggest that neuronatin may be involved in the regulation of cell growth by hormones.
This study suggests the possibility of using neuronatin expression as a tumor marker and prognostic marker. As neuronatin is primarily an embryonal protein, we envisage using it as a serum marker to detect lung carcinomas. Nevertheless, the antineuronatin antibody used here has not been widely used for detection of neuronatin protein from the serum. Furthermore, we could not prepare an authentic positive control of neuronatin protein expression. Validation of the use of neuronatin as a tumor marker will require investigation of the tissue specificity and tumor specificity of this antibody.
